Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
Johnson and Johnson

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CB-839

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for CB-839?

CB-839 is an investigational drug.

There have been 18 clinical trials for CB-839. The most recent clinical trial was a Phase 1 trial, which was initiated on May 9th 2017.

The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are nine US patents protecting this investigational drug and ninety international patents.

Recent Clinical Trials for CB-839
CB-839 in Combination With Niraparib in Platinum Resistant Breast Cancer (BRCA) -Wild-type Ovarian Cancer PatientsUniversity of Alabama at BirminghamPhase 1
CB-839 HCl in Treating Patients With Specific Genetic Mutations and Metastatic or Unresectable Solid Tumors or Malignant Peripheral Nerve Sheath TumorsNational Cancer Institute (NCI)Phase 2
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid TumorsCalithera Biosciences, IncPhase 1/Phase 2

See all CB-839 clinical trials

Clinical Trial Summary for CB-839

Top disease conditions for CB-839
Top clinical trial sponsors for CB-839

See all CB-839 clinical trials

US Patents for CB-839

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CB-839   Start Trial Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA)   Start Trial
CB-839   Start Trial Compositions and methods of treating cancer harboring PIKC3A mutations Case Western Reserve University (Cleveland, OH)   Start Trial
CB-839   Start Trial Combination therapy with glutaminase inhibitors and immuno-oncology agents Calithera Biosciences, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.